MedPath

Treatment of posttraumatic neuralgia - Changes in central pain processing and somatosensory profile after injection of Botulinumtoxin-A compared to placebo

Phase 2
Conditions
posttraumatic neuropathic pain after peripheral nerve leasion
Registration Number
DRKS00013548
Lead Sponsor
Abteilung für SchmerzmedizinBerufsgenossenschaftliches Universitätklinikum Bergmannsheil gGmbH Bochum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting withdrawn before recruiting started
Sex
All
Target Recruitment
45
Inclusion Criteria

Diagnosis of painful neuralgia after peripheral nerve injury, average pain > 4 on numeric rating scale (0-10) in the last two weeks, evidence for nerve leasion (current/anamnestic)

Exclusion Criteria

Age > 18 years, pregnancy, contraindications against injection or FMRI, other neurological or psychiatric diseases, CRPS (Complex regional pain syndrome)

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Rate of patients with relevant pain reduction (50%) within one week after injection of Botulinumtoxin-A in comparison to placebo with pain diaries, pain questionnaires, quantitative sensory testing, fMRI, conditioned pain modulation
Secondary Outcome Measures
NameTimeMethod
Extent of the avergae pain reduction, changes in peripheral sensory system, central pain modulation with pain diaries, pain questionnaires, quantitative sensory testing, fMRI, conditioned pain modulation
© Copyright 2025. All Rights Reserved by MedPath